Why the study?
Does dalteparin once daily improve cost-effectiveness compared to unfractionated heparin 3 times a day for VTE prophylaxis in patients undergoing surgery for gynecologic malignancies?
Does dalteparin once daily improve cost-effectiveness compared to unfractionated heparin 3 times a day for VTE prophylaxis in patients undergoing surgery for gynecologic malignancies?
Routine use of once-daily dalteparin for VTE prophylaxis in malignant gynecologic surgery may provide cost savings compared to unfractionated heparin three times daily.
Answers are grounded in this paper and cite their sources.
May suggest cost savings with dalteparin; leaves open confirmation by randomized economic evaluations.
Venous thromboembolic events (VTEs) are serious complications that may occur in the patient undergoing surgery for gynecologic malignancies. The American College of Chest Physicians recommends unfractionated heparin or low-molecular weight heparin as prophylaxis for deep vein thrombosis and pulmonary embolism in this patient population. Cost-effectiveness analyses comparing unfractionated heparin 3 times a day versus once daily dalteparin using published efficacy and safety data demonstrate cost savings if dalteparin were routinely utilized as VTE prophylaxis. Sensitivity analyses support this finding at the upper end of the range of reported proximal DVT, nonfatal pulmonary embolism, and major bleeding incidences. These findings should be viewed as preliminary, and institutions are encouraged to perform their own cost-effectiveness studies in this patient population.
No takes yet. Share an insight, caveat, or question.
Wade et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: